Forskning ved Københavns Universitet - Københavns Universitet

Forside

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  • Manfred P Wirth
  • William A See
  • David G McLeod
  • Peter Iversen
  • Tom Morris
  • Kevin Carroll
  • Casodex Early Prostate Cancer Trialists' Group
We evaluated the efficacy and tolerability of 150 mg bicalutamide daily given in addition to standard care, in patients with localized or locally advanced prostate cancer.
OriginalsprogEngelsk
TidsskriftJournal of Urology
Vol/bind172
Udgave nummer5 Pt 1
Sider (fra-til)1865-70
Antal sider6
ISSN0022-5347
StatusUdgivet - 1 nov. 2004

ID: 34081195